LOS ANGELES, May 7, 2023 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced new data from the COMMENCE aortic trial, demonstrating low rates of structural valve deterioration (SVD) in ...
CAIRO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new eight-year data showing that patients receiving aortic surgical valves treated with its proprietary RESILIA tissue ...
As it aims to broaden the reach of its replacement heart valves among younger patients, Edwards Lifesciences has put forward new clinical data showing its bioprosthetics can maintain their function ...
Surgical bioprosthetic aortic valves made with bioengineered Resilia tissue (Edwards Lifesciences) appear to suffer less structural deterioration over 8 years compared with similar devices made of ...
Edwards Lifesciences Corporation EW is well-poised to grow in the coming quarters owing to its Surgical Structural Heart, which pioneered the RESILIA tissue. The company’s Transcatheter Aortic Valve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results